Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

Science
Leonela AmoasiiEric N Olson

Abstract

Mutations in the gene encoding dystrophin, a protein that maintains muscle integrity and function, cause Duchenne muscular dystrophy (DMD). The deltaE50-MD dog model of DMD harbors a mutation corresponding to a mutational "hotspot" in the human DMD gene. We used adeno-associated viruses to deliver CRISPR gene editing components to four dogs and examined dystrophin protein expression 6 weeks after intramuscular delivery (n = 2) or 8 weeks after systemic delivery (n = 2). After systemic delivery in skeletal muscle, dystrophin was restored to levels ranging from 3 to 90% of normal, depending on muscle type. In cardiac muscle, dystrophin levels in the dog receiving the highest dose reached 92% of normal. The treated dogs also showed improved muscle histology. These large-animal data support the concept that, with further development, gene editing approaches may prove clinically useful for the treatment of DMD.

References

Mar 16, 1989·Nature·K P Campbell, S D Kahl
Oct 11, 2001·Molecular Genetics and Metabolism·K F O'Brien, L M Kunkel
Jun 26, 2003·Nucleic Acids Research·Luca CartegniAdrian R Krainer
Nov 26, 2003·Lancet Neurology·Francesco MuntoniAlessandra Ferlini
Jul 11, 2006·Human Molecular Genetics·Philip J SmithAdrian R Krainer
Apr 17, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carmela ZincarelliJoseph E Rabinowitz
Jan 22, 2009·Human Mutation·Annemieke Aartsma-RusJohan T den Dunnen
Feb 4, 2014·Journal of Molecular and Cellular Cardiology·Maaike van PuttenAnnemieke Aartsma-Rus
Oct 11, 2014·Nucleic Acids Research·Eva K BrinkmanBas van Steensel
Jun 7, 2015·Annual Review of Genomics and Human Genetics·Simon GuiraudLouis M Kunkel
Nov 18, 2015·Annals of Neurology·Jerry R MendellUNKNOWN Eteplirsen Study Group and Telethon Foundation DMD Italian Network
Jan 2, 2016·Science·Mohammadsharif TabebordbarAmy J Wagers
Jan 21, 2016·The Journal of International Medical Research·Yuanyuan LiJianxin Wu
Dec 6, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jacques P TremblayDominique L Ouellet
Dec 6, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Cy A Stein
Dec 9, 2016·Nucleic Acid Therapeutics·Annemieke Aartsma-Rus, Arthur M Krieg
Nov 2, 2017·The New England Journal of Medicine·Jerry R MendellBrian K Kaspar
Dec 1, 2017·Science Translational Medicine·Leonela AmoasiiEric N Olson

❮ Previous
Next ❯

Citations

Oct 4, 2018·Human Gene Therapy·Thierry VandenDriessche
Jan 3, 2019·Transfusion·Dana V FossRoss C Wilson
Nov 1, 2018·Annual Review of Medicine·Yi-Li MinEric N Olson
Apr 4, 2019·Médecine sciences : M/S·Serge Braun
Apr 5, 2019·Molecular Diagnosis & Therapy·Panayiota PapasavvaCarsten W Lederer
Apr 16, 2019·Nucleic Acids Research·Mareike D HoffmannDominik Niopek
Apr 17, 2019·European Journal of Heart Failure·Petar M SeferovićCarsten Tschöpe
May 8, 2019·Human Gene Therapy Methods·Aojie Cai, Xiangdong Kong
May 24, 2019·Circulation Research·Giuliana G RepettiChristine E Seidman
May 28, 2019·BioTechniques·Jenny Straiton
May 31, 2019·Nature Reviews. Molecular Cell Biology·Adrian Pickar-Oliver, Charles A Gersbach
Aug 8, 2019·Physiology·Courtney S YoungMelissa J Spencer
May 31, 2019·Cellular and Molecular Life Sciences : CMLS·Yong Joon Kim, Joon Kim
Jul 11, 2019·Journal of Muscle Research and Cell Motility·Dominic J Wells
Aug 28, 2019·Journal of Neuromuscular Diseases·Inès BarthélémyLaurent Tiret
Feb 1, 2020·Expert Opinion on Drug Discovery·Nalinda B WasalaDongsheng Duan
Jan 26, 2020·International Journal of Molecular Sciences·Quynh NguyenToshifumi Yokota
Jul 26, 2019·Current Opinion in Neurology·Megan A Waldrop, Kevin M Flanigan
Mar 28, 2020·Genes·Kenji Rowel Q LimToshifumi Yokota
May 2, 2020·Médecine sciences : M/S·Océane BallouheyNicolas Levy
May 8, 2020·Circulation Research·Antonio CannatàMauro Giacca
Sep 30, 2019·Journal of Muscle Research and Cell Motility·Ngoc Thien LamJennifer L Strande
Oct 2, 2019·Nature Communications·Killian S HanlonBence György
Oct 30, 2019·Disease Models & Mechanisms·Belinda S Cowling, Leen Thielemans
Nov 16, 2019·Circulation Research·Eric SchogerLaura C Zelarayán
Feb 20, 2020·Current Opinion in Cardiology·Alexandria M DoerflerWilliam R Lagor
Aug 25, 2020·The CRISPR Journal·Lavina Sierra TayPrashant Mali
Sep 5, 2020·Pediatric Pulmonology·Nicolas J Abreu, Megan A Waldrop
Oct 1, 2020·PloS One·Michael PöhlerVanessa Sandfort
Sep 22, 2018·Nature Reviews. Neurology·Charlotte Ridler
Feb 3, 2019·Nature Reviews. Drug Discovery·Dan WangGuangping Gao
Jun 27, 2019·Human Molecular Genetics·Julie M Crudele, Jeffrey S Chamberlain
Sep 19, 2019·Macromolecular Bioscience·Yu ZouXiangyang Shi
Dec 19, 2019·Journal of Cachexia, Sarcopenia and Muscle·Tirsa L E van WesteringThomas C Roberts
Jan 11, 2020·Frontiers in Bioengineering and Biotechnology·Cecilia VelinoMichele Iafisco
Apr 5, 2020·Neural Regeneration Research·Alejandro Soto-Avellaneda, Brad E Morrison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Virology & CRISPR

This feed focuses on the virology of CRISPR and its use in developing CRISPR-Cas systems. Discover the latest research here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

© 2022 Meta ULC. All rights reserved